Manchester Capital Management LLC grew its position in shares of Iqvia Holdings Inc (NYSE:IQV) by 1,200.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 416 shares of the medical research company’s stock after buying an additional 384 shares during the period. Manchester Capital Management LLC’s holdings in Iqvia were worth $67,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. C J Advisory Inc bought a new position in Iqvia during the 1st quarter worth approximately $27,000. Baystate Wealth Management LLC bought a new position in Iqvia during the 1st quarter worth approximately $27,000. CWM LLC grew its position in Iqvia by 63.4% during the 2nd quarter. CWM LLC now owns 165 shares of the medical research company’s stock worth $27,000 after acquiring an additional 64 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in Iqvia by 140.2% in the 1st quarter. Parkside Financial Bank & Trust now owns 209 shares of the medical research company’s stock worth $30,000 after buying an additional 122 shares during the period. Finally, GWM Advisors LLC lifted its holdings in Iqvia by 306.7% in the 1st quarter. GWM Advisors LLC now owns 20,403 shares of the medical research company’s stock worth $46,000 after buying an additional 15,386 shares during the period. 90.86% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have weighed in on IQV. SunTrust Banks increased their price objective on Iqvia from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Zacks Investment Research upgraded Iqvia from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. Leerink Swann began coverage on Iqvia in a report on Tuesday, May 28th. They issued an “outperform” rating and a $136.38 price objective for the company. Svb Leerink began coverage on Iqvia in a report on Tuesday, May 28th. They issued an “outperform” rating and a $160.00 price objective for the company. Finally, Mizuho upgraded Iqvia from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $150.00 to $175.00 in a report on Friday, June 21st. Three investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. Iqvia presently has an average rating of “Buy” and a consensus price target of $161.13.
Shares of IQV traded up $1.64 on Wednesday, reaching $156.46. The stock had a trading volume of 14,756 shares, compared to its average volume of 1,126,415. The firm has a market capitalization of $30.39 billion, a price-to-earnings ratio of 30.63, a price-to-earnings-growth ratio of 1.89 and a beta of 0.88. The company has a debt-to-equity ratio of 1.72, a quick ratio of 1.14 and a current ratio of 1.14. The company has a 50-day simple moving average of $157.44 and a 200-day simple moving average of $144.39. Iqvia Holdings Inc has a 12-month low of $104.90 and a 12-month high of $164.13.
Iqvia (NYSE:IQV) last released its earnings results on Wednesday, July 24th. The medical research company reported $1.39 EPS for the quarter, beating the Zacks’ consensus estimate of $1.38 by $0.01. The company had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.70 billion. Iqvia had a return on equity of 15.95% and a net margin of 2.31%. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.29 EPS. On average, analysts expect that Iqvia Holdings Inc will post 5.87 EPS for the current fiscal year.
Iqvia Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.